1. Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000.
2. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных   противовоспалительных   препаратов.   Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.
3. Day R, Graham G, Whelton A. The position of paracetamol in the world of analgesics. Am J Therap 2000; 7: 51–5.
4. Schnitzer T, Weaver A, Polis A. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 2005; 32: 1093–105.
5. Pincus T, Koch G, Lei H et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004; 63: 931–9.
6. Boureau F, Schneid H, Zeghari N et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of knee or hip. Ann Rheum Dis 2004; 63: 1028–35.
7. Zhu K, Devine A, Dick I, Prince R. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine 2007; 32 (18): 2012–8.
8. Lee T, Bartle B, Weiss K. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007; 120 (1): 98–104.
9. Goodson N, Brookhart A, Symmons D et al. Non-steroidal antiinflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68 (3): 367–72.
10. Singh G. Recent consideration in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31–8.
11. Lain L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessery? Rew Gastroenterol Dis 2004; 4: 33–41.
12. Lanas A. Prevention and treatment of NSAID-induced gastrointestinal injury. Curr Treat Options Gastroenterol 2006; 9: 147–56.
13. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска. Тер. арх. 2008; 5: 62–6.
14. Hochman J, Shah N. What Price Pain Relief? Circulation 2006; 113: 2868–70.
15. Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009; 11 (1): 31–5.
16. Aw T-J, Haas S, Liew D. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490–6.
17. Lanas A, Tornero J, Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010; 69 (8): 1453–8.
18. Fries J, Kristen N, Bennet M et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2433–40.
19. Lanas A, Garc?a-Rodr?guez LA, Polo-Tom?s M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104 (7): 1633–41.
20. Laharie D, Droz-Perroteau C, B?nichou J et al. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010; 69 (3): 295–302.
21. Inotai A, Hank? B, M?sz?ros A. Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol Drug Saf 2010; 19 (2): 183–90.
22. Mattia C, Ciarcia S, Muhindo A, Coluzzi F. Nimesulide: 25 years later. Minerva Med 2010; 101 (4): 285–93.
23. Насонов Е.Л. Эффективность и переносимость нестероидного противовоспалительного препарата. Нимесулид: новые данные. РМЖ. 2001; 15: 6–8.
24. Rainsford K. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006; 14 (3–4): 120–37.
25. Bennett A. Nimesulide a well established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Therapeutic Roles of Selective COX-2 Inhibitors. Ed. Vein JR, Botting RM. William Harvey Press: 524–40.
26. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
27. Wober W, Rahlfs V, Buchl N et al. Comparative efficacy and safety of the non-steroidal anti-inflammatory drugs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J Clin Pract 1998; 52 (3): 169–75.
28. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
29. Konstantinovic L, Kahjun Z, Milovanovic A et al. Acute low back pain with radiculopathy: a double – blind, randomized, placebocontrolled study. Photomed Laser Surg 2010; 28 (4): 555–60.
30. L?cker P, Pawlowski C, Friedrich I et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994; 14 (2): 29–38.
31. Huskisson E, Macciocchi A, Rahlfs V et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr Ther Res 1999; 60: 253–65.
32. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55 (8): 510–14.
33. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract 2004; (Suppl.) 144: 27–32.
34. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 1081–90.
35. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411–20.
36. Минушкин О.Н. Использование препарата «Найз» у больных, страдающих сочетанной патологией суставов и поражением верхних отделов желудочно-кишечного тракта. Научно-практическая ревматология. 2003; 5: 72–6.
37. Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. и др. Эффективность и безопасность монотерапии высокими дозами НПВП при раннем артрите. РМЖ. 2006; 16: 24–9.
38. Каратеев А., Каратеев Д., Насонов Е. Гастродуоденальная переносимость нимесулида (НИМЕСИЛ, Berlin Chemie) у больных с язвенным анамнезом: первое проспективное исследование безопасности селективных ЦОГ-2 ингибиторов у больных с высоким риском развития НПВП-индуцированных гастропатий. Науч.-практ. ревматол. 2003; 1: 45–8.
39. Helin-Salmivaara A, Virtanen A, Veslainen R et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart 2006; 27: 1657–63.
40. Мазуров В.И., Лила А.М. Отчет о результатах пилотного исследования по сравнительной оценке влияния найза (нимесулида) и диклофенака на гемодинамические показатели у больных остеоартрозом в сочетании с эссенциальной артериальной гипертензией, кафедра терапии 1 им. Э.Э.Эйхвальда с курсом ревматологии Медицинской академии последипломного образования. СПб., 2007.
41. Барскова В.Г., Насонова В.А., Цапина Т.Н. и др. Эффективность и безопасность применения нимесила у больных с подагрическим артритом. Клин. мед. 2004; 82 (12): 49–54.
42. Каратеев А.Е., Насонова В.А. НПВП-ассоциированная гепатопатия: проблема нимесулида. Науч.-практ. ревматол. 2004; 1: 34–7.
43. Каратеев А.Е., Барскова В.Г. Безопасность нимесулида: эмоции или взвешенная оценка? Cons. Med. 2007; 9: 60–4.
44. Rainsford K. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
45. HELSINN’s response. На сайте: HELSINN, 2002, 12. http://www.pharmabiz.com.
46. Irish Board Suspends Marketing of Drugs Containing Nimesulide http://www.imb.ie.
47. Press release. European Medicines Agency recommends restricted use of nimesulid-containing medicinal products. Doc. Ref. EMEA/432604/2007. На сайте: http://www.emea.europa.eu.
48. Venegoni M, Da Cas R, Menniti-Ippolito F, Traversa G. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann Ist Super Sanita 2010; 46 (2): 153–7.
49. БОЛЬ: информационный портал. Новости: Казнить или помиловать нимесулид? http://www.paininfo.ru/press/1164.html
50. Traversa G, Bianchi C, Da Cas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ 2003; 327: 18–22.
51. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике. РМЖ. 2009; 17 (21): 1466–72.